Reserpine pretreatment prevents increases in extracellular striatal dopamine following L-DOPA administration in rats with nigrostriatal denervation.
about
Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic ImplicationsActivation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered L-DOPA in the striatum with nigrostriatal denervation.Chronic L-dopa decreases serotonin neurons in a subregion of the dorsal raphe nucleusPresynaptic effects of levodopa and their possible role in dyskinesia.Imbalanced Dopaminergic Transmission Mediated by Serotonergic Neurons in L-DOPA-Induced Dyskinesia.Depression of Serotonin Synaptic Transmission by the Dopamine Precursor L-DOPASerotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian ratsMultisite intracerebral microdialysis to study the mechanism of L-DOPA induced dopamine and serotonin release in the parkinsonian brainModeling and imaging cardiac sympathetic neurodegeneration in Parkinson's disease.Contribution of serotonergic transmission to the motor and cognitive effects of high-frequency stimulation of the subthalamic nucleus or levodopa in Parkinson's disease.The immunological challenges of cell transplantation for the treatment of Parkinson's disease.Impairment of Serotonergic Transmission by the Antiparkinsonian Drug L-DOPA: Mechanisms and Clinical ImplicationsAnti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptorsMathematical insights into the effects of levodopa.Deuterium-substituted L-DOPA displays increased behavioral potency and dopamine output in an animal model of Parkinson's disease: comparison with the effects produced by L-DOPA and an MAO-B inhibitor.Effects of antipsychotic treatment on cognition in healthy subjects.Perinatal 6-Hydroxydopamine to Produce a Lifelong Model of Severe Parkinson's Disease.Striatal glutamate induces retrograde excitotoxicity and neuronal degeneration of intralaminar thalamic nuclei: their potential relevance for Parkinson's disease.Differential contribution of storage pools to the extracellular amount of accumbal dopamine in high and low responders to novelty: effects of reserpine.Exendin-4 treatment enhances L-DOPA evoked release of striatal dopamine and decreases dyskinetic movements in the 6-hydoxydopamine lesioned rat.alpha2-Noradrenergic receptors activation enhances excitability and synaptic integration in rat prefrontal cortex pyramidal neurons via inhibition of HCN currents.Antidopaminergic medication in healthy subjects provokes subjective and objective mental impairments tightly correlated with perturbation of biogenic monoamine metabolism and prolactin secretion.
P2860
Q21129423-802D504E-3F13-4BA0-BF8E-5B4BF6BBB875Q32134305-53AC0169-4834-4993-830D-09471AE6B26DQ34360660-427809CC-8A68-4526-A5C9-8A81F5A449D5Q35040280-BAEF84FD-0BE3-4BF5-829E-2EDEBD75339BQ35324977-92730B7A-1937-4E99-A075-1C7BCAD53A8BQ35952108-E9838726-D264-4108-A7B0-1AB501170E82Q36243814-2294B750-8262-4706-B8E3-BB7E9F07A259Q36851713-D4DDD01F-AFC1-42FA-BB69-DC17E30DA452Q37711062-85E1284D-56E9-415B-AA3E-1002B9EF48F7Q37973611-FEA00896-7CB4-48EB-A1B6-7C08FB12065DQ38004257-3C395042-256C-4C39-AADD-6752154C6394Q41684008-1F43044E-0825-4D3C-B08E-7BC2E06467B3Q42121362-C567CD63-8328-4578-BF14-54B6D3D0EE9AQ42224924-688016C1-53AD-4E1B-8629-64A453CE3606Q42705333-E7063D6B-BABC-4298-9F04-785F90038963Q45743617-F685A524-D0F3-455D-A073-553B16A01255Q46652882-A1A5EEC2-0637-4791-A5B4-4979038BBC19Q48092207-A866A5E9-2F34-451C-B94D-5F6E6B314634Q48348492-059A548A-0172-428E-8EC4-FF5C1B30BCA5Q48586476-70774414-AC39-43B4-8882-911CB66EE408Q51972660-CA2EF238-D7EB-41C0-9C3D-3AA5E0E1DD80Q55253133-AB200962-4255-4ADE-8AC3-D2D2A6EAED27
P2860
Reserpine pretreatment prevents increases in extracellular striatal dopamine following L-DOPA administration in rats with nigrostriatal denervation.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Reserpine pretreatment prevent ...... ith nigrostriatal denervation.
@en
Reserpine pretreatment prevent ...... ith nigrostriatal denervation.
@nl
type
label
Reserpine pretreatment prevent ...... ith nigrostriatal denervation.
@en
Reserpine pretreatment prevent ...... ith nigrostriatal denervation.
@nl
prefLabel
Reserpine pretreatment prevent ...... ith nigrostriatal denervation.
@en
Reserpine pretreatment prevent ...... ith nigrostriatal denervation.
@nl
P2093
P2860
P1476
Reserpine pretreatment prevent ...... ith nigrostriatal denervation.
@en
P2093
P2860
P304
P356
10.1046/J.1471-4159.2000.0740263.X
P407
P577
2000-01-01T00:00:00Z